DNA-microarray analysis of brain cancer: molecular classification for therapy.
Primary brain tumours are among the most lethal of all cancers, largely as a result of their lack of responsiveness to current therapy. Numerous new therapies hold great promise for the treatment of patients with brain cancer, but the main challenge is to determine which treatment is most likely to benefit an individual patient. DNA-microarray-based technologies, which allow simultaneous analysis of expression of thousands of genes, have already begun to uncover previously unrecognized patient subsets that differ in their survival. Here, we review the progress made so far in using DNA microarrays to optimize brain cancer therapy.
Mischel
Paul S
PS
Department of Pathology and Laboratory Medicine, the Henry E. Singleton Brain Cancer Research Program at the David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA. pmischel@mednet.ucla.edu
Cloughesy
Timothy F
TF
Nelson
Stanley F
SF
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics; D001932:Brain Neoplasms / Q000145:classification* / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D015894:Genome, Human; D005910:Glioma / Q000175:diagnosis / Q000235:genetics; D006801:Humans; D008527:Medulloblastoma / Q000175:diagnosis / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D015203:Reproducibility of Results
D014408:Biomarkers, Tumor